EYPT News and Press, EyePoint Pharmaceuticals Inc. From 10/31/23

WATERTOWN, Mass., Oct. 31, 2023 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a company committed to developing and commercializing therapeutics to improve the lives of patients with retinal diseases, today announced it will host a virtual key opinion leader (KOL) event on Th...

WATERTOWN, Mass., Oct. 30, 2023 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a pharmaceutical company committed to developing and commercializing therapeutics to improve the lives of patients with retinal diseases, today announced that the Company will present at upcoming me...

WATERTOWN, Mass., Oct. 25, 2023 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a company committed to developing and commercializing therapeutics to improve the lives of patients with retinal diseases, today announced it will host a conference call and live webcast at 8:30 a.m...

2023-10-20 17:38:28 ET Eyepoint Pharmaceuticals ( NASDAQ: EYPT ) on Friday filed a prospectus for a mixed securities shelf offering of up to $350 million. This prospectus is not an offer to sell these securities. SEC Filing For further details see: Eyepoint P...

– Stuart Duty appointed to EyePoint’s Board of Directors – – George Elston promoted to Executive Vice President – WATERTOWN, Mass., Oct. 16, 2023 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a company committed to ...

2023-10-05 05:30:00 ET More on Markets As 10-year Treasury yield pushes higher, Wolfe Research calls for 5% by year end Correction could be coming for mega caps - Wells Fargo Berenberg: Get defensive with healthcare, utilities and telecoms BlackRock is overwe...

2023-09-11 15:20:00 ET Shares of EyePoint Pharmaceuticals (NASDAQ: EYPT) were up more than 20% as of 2:30 p.m. ET on Monday after the healthcare company announced interim masked trial data for its lead therapy to treat two different eye diseases. The stock is up more than 36% so...

2023-09-11 14:21:30 ET More on EyePoint Seeking Alpha’s Quant Rating on EyePoint Pharmaceuticals Historical earnings data for EyePoint Pharmaceuticals Financial information for EyePoint Pharmaceuticals EyePoint: Well-Funded And Catalyst-Rich, But Not W...

- Interim analysis of masked data shows EYP-1901 is well tolerated with no reported drug-related ocular or systemic serious adverse events in Phase 2 PAVIA clinical trial in non-proliferative diabetic retinopathy - - Updated interim analysis of masked safety data of Phase 2 DAVIO 2 tria...

2023-09-05 17:18:20 ET Gainers: AeroVironment ( AVAV ) +13% . Consolidated Water  ( CWCO ) +6% . GitLab  ( GTLB ) +6% . Backblaze ( BLZE ) +5% . Gogo ( GOGO ) +5% . Losers: CSG Systems International ( CSGS ) -...